Aug. 19, 2026—Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience Corp. are collaborating to support the genomic screening of blood-based samples from patients with lung cancer as part of the LC-SCRUM-Asia project in Japan. The project is expected to include about 2,000 patients over a two-year period. The participating organizations plan to begin testing this month following approval of a revision to the LC-SCRUM-Asia project protocol.
“Rapid and reliable genomic testing is essential for identifying patients who may benefit from biomarker-driven clinical studies and emerging precision therapies,” Dr. Koichi Goto of LC-SCRUM-Asia, said in a joint press release. “The use of OncoReveal Essential+ through LSI Medience will provide the LC-SCRUM-Asia network with a highly accurate and accessible liquid biopsy solution for analyzing cfDNA and cfRNA from patients with non-small cell lung cancer, while supporting the rapid turnaround needed for clinical research.”
Pillar’s OncoReveal Essential+ assay has been validated at LSI Medience for use as a screening test for circulating cell-free DNA and cell-free RNA samples collected from patients with lung cancer participating in the LC-SCRUM-Asia project. Testing will be performed by LSI Medience to support identification of genomic alterations relevant to the project’s research objectives.